| Literature DB >> 34473004 |
Hafiz Khan1, Drew Rasmussen1, Kemesha Gabbidon2, Komaraiah Palle3, Aamrin Rafiq4, Mohammad Faysel5, Sharda Singh6, P Hemachandra Reddy6.
Abstract
OBJECTIVES: Breast cancer is the second highest female mortality rate in Texas for all races and ethnicities, except for Hispanics. Interestingly, Hale County is a rural underserved county in West Texas which experiences a lower rate of cancer, has higher age-adjusted mortality rates (26.2/100 000), on average, compared to all of Texas (23.1/100 000). The purpose of this study was to determine the relationship between sociodemographic variables and breast cancer outcomes in underserved Hale County which contributed to the highest mortality rate in Texas.Entities:
Keywords: Hale County; breast cancer; rural West Texas; sociodemographic variables
Mesh:
Year: 2021 PMID: 34473004 PMCID: PMC8419545 DOI: 10.1177/10732748211042125
Source DB: PubMed Journal: Cancer Control ISSN: 1073-2748 Impact factor: 3.302
Differences Between Survival Times for Race/Ethnicity Groups (in Days) of Women Breast Cancer Patients in Hale County (1995–2014).
| Year at diagnosis | White non-Hispanic mean difference (P-value) | White Hispanic T-test value (P-value) | Other T-test value (P-value) |
|---|---|---|---|
| <45 vs 45–55 | 181.54 (.85) | −733.90 (.29) | −387.25 (.87) |
| <45 vs 55–64 | 509.71 (.54) | −498.95 (.42) | −835.50 (.64) |
| <45 vs 65–74 | 1247.91 (.08) | −229.19 (.71) | 153.54 (.92) |
| <45 vs 75+ | 1727.65 (.02*) | 123.67 (.92) | −594.25 (.73) |
| 45–55 vs 55–64 | 328.17 (.52) | 234.95 (.73) | −448.25 (.85) |
| 45–55 vs 65–74 | 1066.36 (.02*) | 504.71 (.50) | 540.79 (.78) |
| 45–55 vs 75+ | 1546.10 (.01*) | 857.57 (.54) | −207.00 (.92) |
| 55–64 vs 64–74 | 738.20 (.05*) | 269.76 (.67) | 989.04 (.50) |
| 55–64 vs 75+ | 1217.94 (.01*) | 622.62 (.61) | 241.25 (.88) |
| 65–75 vs 75+ | 479.74 (.16) | 352.86 (.77) | −747.786 (.60) |
| Insurance | |||
| Private insurance vs public insurance | 240.04 (.34) | −232.05 (.51) | — |
| Private insurance vs no insurance | −828.29 (.45) | .72 (.49) | — |
| Private insurance vs NOS, unknown | −1494.62 (.01*) | −2205.53 (.01*) | — |
| Public insurance vs No insurance | −1068.33 (.22) | 1.09 (.29) | — |
| Public insurance vs NOS, unknown | −1734.66 (.01*) | −1973.49 (.01*) | −1759.90 (.27) |
| No insurance vs NOS, unknown | −666.34 (.77) | −2.25 (.03*) | — |
| Grade | |||
| Grade I vs grade II | 425.84 (.36) | 123.52 (.89) | −2613.20 (.18) |
| Grade I vs grade III | 784.95 (.12) | .62 (.54) | −1.13 (.29) |
| Grade I vs grade IV | 2412.00 (.25) | — | — |
| Grade I vs unknown | 370.15 (.53) | −.05 (.96) | −2.02 (.11) |
| Grade II vs grade III | 359.11 (.29) | .50 (.62) | — |
| Grade II vs grade IV | 1986.16 (.31) | — | — |
| Grade II vs unknown | −55.69 (.89) | −.21 (.83) | −.42 (.69) |
| Grade III vs grade IV | 1627.05 (.44) | — | — |
| Grade III vs unknown | −414.80 (.35) | −.82 (.42) | −1.20 (.26) |
| Grade IV vs unknown | −2041.85 (.40) | — | — |
| Stage | |||
| In situ vs localized | −179.50 (.78) | −530.69 (.49) | 416.67 (.84) |
| In situ vs regional by direct extension | −2211.87 (.31) | 1308.21 (.27) | — |
| In situ vs regional-to- regional lymph | −439.71 (.56) | 749.43 (.47) | −798.80 (.71) |
| In situ vs regional | 652.63 (.50) | 3080.46 (.01*) | — |
| In situ vs distant metastasis | 3237.13 (.01*) | 4630.21 (.01*) | 2586.50 (.40) |
| In situ vs unstaged | 1861.91 (.01*) | 3350.71 (.01*) | 1069.33 (.57) |
| Localized vs regional by direct extension | −2032.37 (.37) | 1838.90 (.14) | — |
| Localized vs regional- to-regional lymph | −260.22 (.63) | 1280.11 (.18) | −1215.50 (.37) |
| Localized vs regional | 832.13 (.38) | 3611.15 (.01*) | — |
| Localized vs distant metastasis | 3416.63 (.01*) | 5160.90 (.01*) | 2169.83 (.22) |
| Localized vs unstaged | 2041.41 (.01*) | 3881.40 (.01*) | 652.67 (.58) |
| Regional by direct extension vs regional- to-regional lymph | 1772.15 (.50) | −558.79 (.74) | — |
| Regional by direct extension vs regional | 2864.50 (.19) | 1772.25 (.10) | — |
| Regional by direct extension vs distant metastasis | 5449.00 (.01*) | 3322.00 (.01*) | — |
| Regional by direct extension vs unstaged | 4073.78 (.01*) | 2042.50 (.02*) | — |
| Regional to regional lymph vs regional | 1092.35 (.32) | 2331.04 (.08) | — |
| Regional to regional lymph vs distant metastasis | 3676.85 (.01*) | 3880.79 (.05*) | 3385.30 (.09) |
| Regional to regional lymph vs unstaged | 2301.62 (.01*) | 2601.29 (.01*) | 1868.13 (.16) |
| Regional vs distant metastasis | 2584.50 (.02*) | 1549.75 (.13) | — |
| Regional vs unstaged | 1209.28 (.02*) | 270.25 (.66) | — |
| Distant metastasis vs unstaged | −1375.22 (.03*) | −1279.50 (.14) | −1517.17 (.31) |
| Zip code | |||
| 79 311 vs 79 041 | .13 (.90) | .71 (.49) | −.73 (.54) |
| 79 311 vs 79 072 | .31 (.75) | −.01 (.99) | −1.20 (.25) |
| 79 311 vs other | 2.34 (.03*) | 1.02 (.34) | — |
| 79 041 vs 79 072 | .16 (.88) | −.85 (.40) | −.51 (.61) |
| 79 041 vs other | 1.93 (.07) | .34 (.75) | — |
| 79 072 vs other | 2.05 (.04*) | .96 (.34) | — |
Note. NOS, not otherwise specified; —, not applicable due to low frequency, *P < .05.
Hazard ratios, 95% confidence intervals, and significance for women breast cancer patients in Hale County (1995–2014).
| All-cause death | Breast cancer death | Other cause death | ||||
|---|---|---|---|---|---|---|
| HR (CI) | Significance (P-value) | HR (CI) | Significance (P-value) | HR (CI) | Significance (P-value) | |
| Race/ethnicity | ||||||
| White non-Hispanic | 1.155 (.585−2.281) | .677 | .579 (.244−1.374) | .215 | 2.306 (.726−7.321) | .156 |
| White Hispanic | 1.175 (.568−2.431) | .664 | .879 (.351−2.203) | .784 | 1.767 (.523−5.975) | .36 |
| Other | 1.000 (ref) | — | 1.000 (ref) | — | 1.000 (ref) | — |
| Insurance | ||||||
| Private insurance | .561 (.245−1.286) | .172 | 1.406 (.587−3.367) | .445 | N/A | — |
| Public insurance | .884 (.516−1.514) | .652 | 1.344 (.658−2.745) | .418 | .569 (.243−1.333) | .194 |
| No insurance | 1.588 (.389−6.485) | .519 | 3.749 (.892−15.750) | .071 | N/A | — |
| NOS, unknown | 1.000 (ref) | — | 1.000 (ref) | — | 1.000 (ref) | — |
| Grade | ||||||
| Grade I | 1.000 (ref) | — | 1.000 (ref) | — | 1.000 (ref) | — |
| Grade II | 1.087 (.945−1.251) | .260 | 4.889 (1.228−18.538) | .011* | .873 (.791−.962) | .003** |
| Grade III | 1.142 (.993−1.316) | .070 | 10.788 (2.428−45.54) | .009** | .573 (.541−.607) | .002** |
| Grade IV | 5.089 (1.226−21.162) | .010* | N/A | — | 7.863 (2.032−30.419) | .001** |
| Unknown | .943 (.529−1.684) | .844 | 10.101 (1.259−76.923) | .024* | .421 (.207−.855) | .017* |
| Stage | ||||||
| In situ | .462 (.237−.901) | .024* | N/A | — | 1.103 (.521−2.338) | .797 |
| Localized | .609 (.396−.936) | .024* | .207 (.091−.473) | .0001*** | 1.182 (.668−2.090) | .565 |
| Regional by direct extension | .923 (.286−2.982) | .894 | N/A | — | 2.229 (.657−7.564) | .198 |
| Regional-to-regional lymph | .512 (.302−.870) | .013* | .336 (.140−.802) | .014 | .791 (.392−1.597) | .513 |
| Regional | 1.810 (.920−3.559) | .086 | 2.082 (.913−4.749) | .081 | 1.372 (.409−4.596) | .608 |
| Distant metastasis | 10.421 (4.764−22.795) | .0001*** | 7.829 (2.646−23.162) | .0001*** | 14.287 (4.587−44.495) | .0001*** |
| No staging | 1.000 (ref) | — | 1.000 (ref) | — | 1.000 (ref) | — |
| Age | ||||||
| <45 | 1.000 (Ref) | — | 1.000 (ref) | — | 1.000 (ref) | — |
| 45-54 | .510 (.238−1.091) | .083 | .507 (.195−1.316) | .162 | .577 (.163−2.050) | .395 |
| 55-64 | 1.026 (.533−1.975) | .938 | .647 (.274−1.528) | .321 | 1.791 (.614−5.226) | .286 |
| 65-74 | 1.484 (.785−2.808) | .225 | .803 (.348−1.850) | .606 | 2.870 (1.004−8.204) | .049* |
| 75+ | 2.349 (1.252−4.405) | .008** | .794 (.324−1.944) | .613 | 5.513 (1.970−15.431) | .001* |
| Zip code | ||||||
| 79 311 | .679 (.22−2.081) | .499 | .371 (.062−2.236) | .279 | .868 (.190−3.973) | .855 |
| 79 041 | .532 (.172−1.650) | .275 | .455 (.083−2.505) | .365 | .566 (.120−2.670) | .472 |
| 79 073 | .605 (.221−1.654) | .328 | .669 (.161−2.772) | .579 | .559 (.135−2.317) | .423 |
| Other | 1.000 (ref) | — | 1.000 (ref) | — | 1.000 (ref) | — |
Note. CI, confidence interval, —, not applicable due to low frequency; Ref, referent group, P * < .05; ** < .01; *** < .001.
Figure 1.Kaplan–Meier curves of survival probability for women in Hale County (1995–2014).
Figure 2.Frequencies of variables by death cause for women in Hale County (1995–2014).